Our Publications
As a science-driven company, we proudly publish numerous scientific papers every year in high-impact journals. Please feel free to contact our Science-team if you have questions or comments to our publications, or proposals for new scientific collaborations: science@nbcd.com3 publications found
February 25, 2022
Osteoarthritis (OA) development programmes face challenges due to discordance between structural changes and symptoms. A novel cathepsin-K inhibitor, MIV-711, recently reported structural benefits, but did not demonstrate a significant difference from placebo in symptoms. Previous work suggests that pain from non-target joints may confound OA pain outcomes. We therefore conducted an exploratory analysis in participants with predominantly unilateral knee pain from the MIV-711-201 trial.
Journals:
Clinical and Experimental Rheumatology
Authors:
Osteoarthritis
May 07, 2021
The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safety results.
Journals:
Annals of the Rheumatic Diseases
Authors:
Eckstein F
, Hochberg MC
, Guehring H
, Moreau F
, Ona V
, Bihlet AR
, Byrjalsen I
, Andersen JR
, Daelken B
, Guenther O
, Ladel C
, Michaelis M
, Conaghan PG
Osteoarthritis
March 11, 2021
To assess pain outcomes and cartilage thickness change in a subgroup at risk (SAR) of further progression in the FORWARD trial of knee osteoarthritis patients treated with sprifermin.
Journals:
Seminars in Arthritis and Rheumatism
Authors:
Guehring H
, Moreau F
, Daelken B
, Ladel C
, Guenther O
, Bihlet AR
, Wirth W
, Eckstein F
, Hochberg MC
, Conaghan PG
Osteoarthritis